This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 8, 2012; 09:00 am ET
Dr. Mitchell Steiner - Chief Executive Officer
Marc Hanover - President & Chief Operating Officer
AnalystsJoel Sendek - Stifel Nicolaus
David Nierengarten - Wedbush Securities
Biren Amin - Jefferies
Ryan Martin - Lazard Capital Markets
Howard Liang - Leerink Swann
Good day ladies and gentlemen and welcome to the GTx Inc corporate update and second quarter 2012 financial results conference call. My name is Tahisha and I will be your operator for today.
At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. (Operator Instructions).
I would now like to turn the conference over to your host for today, Dr. Mitchell Steiner, CEO of GTx, please proceed.
Dr. Mitchell Steiner
Thank you operator. I will be making forward-looking comments during today’s call and I direct you to the press release of our financial results we filed today and the Quarterly Report on Form 10-Q we filed May 10, 2012 with the SEC, where we discuss the risks and uncertainties that affect our business.
GTx has made good progress in advancing our two late stage clinical programs, enobosarm for the prevention and treatment of muscle wasting in patients who have advanced non-small cell lung cancer and Capesaris as a secondary hormonal therapy in men with castration resistant prostate cancer.
As with the Enobosarm program, we are currently enrolling subjects into two international pivotal Phase III clinical trials called POWER 1 and POWER 2 in over 80 clinical sites located in the United States, Europe and South America.